Romatoid Artritte Göz Bulgularının Değerlendirilmesi

Yıl 2015, , 37 - 44, 05.01.2016

Rukiye Yazıcı Turgut Kültür Alper Yazıcı

https://doi.org/10.24938/kutfd.124911

Öz

Romatoid artritli hastalarda göz sıklıkla tutulabilmektedir. Gerek hastalığın seyrindeki inflamasyon, gerekse de kullanılan ilaçlara bağlı olarak göz etkilenmektedir. Genellikle hastalığın ağır seyrettiği olgularda ve ileri yaş kadın hastalarda göz tutulumu daha sık görülmektedir. Artritin ortalama süresi ve seropozitivitenin ortalama süresiyle oküler komplikasyon varlığı arasında belirgin korelasyon söz konusudur. Romatoid artrit hastalarının bir kısmında hastalığın tedavisi göz bulgularının düzelmesi için yeterli olabilmesine rağmen bir grup hastada ise gözdeki hastalığın ilave ilaçlarla ayrıca tedavisi gerekli olabilmektedir. Bu makalede romatoid artritte görülen göz bulguları, oluşum mekanizmaları, klinikleri ve tedavi protokollerinin değerlendirilmesi amaçlanmıştır.

Anahtar Kelimeler

involvement, complications Rheumatoid Arthritis, ocular

Kaynakça

• Gümüşdiş G: Bağ Dokusu Hastalıkları: Romatoid artrit. Gümüşdiş G Doğanavşargil E (eds). Klinik Romatoloji, Deniz Matbaası, İstanbul: 1999; 269-79.
• Reddy SC, Rao UR. Ocular complications of adult rheumatoid arthritis. Rheumatology International. 1996; 16(2): 49-52.
• Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 2009; 28(9): 1023-7.
• Foster CS, Yüksel E, Anzaar F, Ekong AS. Dry Eye Syndrome. eMedicine Specialties, Ophthalmology, Lacrimal System. Updated: Nov 15, 2010.
• Akça BS, Akova YA. Kuru göz tedavisinde güncel tedavi yöntemleri. J Exp Clin Med. 2012; 29: 58-65.
• Bron AJ. Diagnosis of dry eye. Survey of Ophthalmology. 2001; 45(2): S221-6.
• Savini G, Prabhawasat P, Kojima T, Grueterich M, Espana E, Goto E. The challenge of dry eye diagnosis. Clin Ophthalmol. 2008; 2(1): 31-5.
• -
• Liu H, Begley C, Chen M, Bradley A, Bonanno J, McNamara NA, Nelson JD, Simpson T. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmology Vis Sci. 2009; 50(8): 3671-9.
• Dogru M, Tsubota K. New insights into the diagnosis and treatment of dry eye. Ocul Surf. 2004; 2(2): 59-75.
• Oguz H. Noninvasive tear meniscometry in dry eye patients with Sjogren syndrome. Am J Ophthalmol. 2008; 145(1): 184-5.
• Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003; 217(2): 89-98.
• Lekhanont K, Park CY, Smith JA, Combs JC, Preechawat P, Suwan-Apichon O, Rangsin R, Chuck RS. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. J Ocul Pharmacol Ther. 2007; 23(1): 27-34.
• Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106(4): 811-6.
• Tatlıpınar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. The British Journal of Ophthalmology. 2005; 89(10): 1363-7.
• Gündüz K, Özdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol (Copenh). 1994; 72(4): 438-42.
• Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Archives of Ophthalmology. 2000; 118(11): 1489-96.
• Yılmaz S, Saklamaz A, Demir C, Mermut İ, Şener G, Maden A. Application of utologous serum in dry eye patients. İzmir Atatürk Eğitim Hastanesi Tıp Dergisi. 2004; 42: 161-5.
• Pınarcı EY, Pelit A, Bozkırlı D, Canbolat ET. . Primary Sjögren Syndrome: Case report. Cukurova Medical Journal. 2013; 38 (4): 818-22.
• Aslı C, Esen K. Use of Autologous Serum Eye Drops in Ophthalmology Literature: Expanding Indications: Review. Turkiye Klinikleri J Ophthalmol. 2010; 19(3): 161-70.
• Hamideh F, Prete PE. Ophthalmologic manifestations of rheumatic diseases. Seminars in Arthritis and Rheumatism. 2001; 30(4) :217-41.
• Sims J. Scleritis: presentations, disease associations and management. Postgraduate Medical Journal. 2012; 88(1046): 713-8.
• Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheumatic Diseases Clinics of North America. 2007; 33(4): 835-54.
• Sainz de la Maza M, Foster CS, Jabbur NS, Baltatzis S. Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy. Archives of Ophthalmology. 2002; 120(1): 15-9.
• McCluskey PJ, Watson PG, Lightman S, Haybittle J, Restori M, Branley M. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology. 1999; 106(12): 2380-6.
• Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocular Immunology and Inflammation. 2005; 13(5): 335-51.
• Hata M, Nakamura T, Sotozono C, Kumagai K, Kinoshita S, Kurimoto Y. Atypical continuous keratitis in a case of rheumatoid arthritis accompanying severe scleritis. Cornea. 2012; 31(12): 1493-6.
• Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. American Journal of Ophthalmology. 2000; 130(4): 469-76.
• Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Survey of Ophthalmology. 2005; 50(4): 351-63.
• Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis and Rheumatism. 2001; 45(3): 252-7.
• Birch MK, Barbosa S, Blumhardt LD, O'Brien C, Harding SP. Retinal venous sheathing and the blood-retinal barrier in multiple sclerosis. Archives of Ophthalmology. 1996; 114(1): 34-9.
• Walton RC, Ashmore ED. Retinal vasculitis. Current Opinion in Ophthalmology. 2003; 14(6): 413-9.
• Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. American Journal of Ophthalmology. 2000; 130(4): 492-513.
• Dunn JP. Review of immunosuppressive drug therapy in uveitis. Current Opinion in Ophthalmology. 2004; 15(4): 293-8.
• Parks MM. Brown’s Syndrome. Ed. Duane TD JECoOmas-m, 1th ed. Philadelphia 1988. JBLippincott Co. 1988; chap 20; 4-5.
• Gerinec A, Slivkova D. Surgery in congenital Brown's syndrome. Cesk Slov Oftalmol. 1997; 53(2): 76-9.